As of June 30, 2024, the Company had cash, cash equivalents and marketable securities totaling $226.1 million, which provides projected cash runway into 2026. Second quarter of 2024 compared to the ...
As of June 30, 2025, the Company had cash, cash equivalents and marketable securities totaling $138.5 million. Together with net proceeds of approximately $65.1 million from the July 2025 public ...
BALA CYNWYD, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results